Our top pick for
Celularity Inc is a shell companies business based in the US. Celularity shares (GXGX) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||$10.13|
|52-week range||$8.07 - $12.17|
|50-day moving average||$10.06|
|200-day moving average||$10.14|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.49|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-05)||N/A|
|1 month (2021-09-12)||N/A|
|3 months (2021-07-16)||-0.69%|
|6 months (2021-04-15)||0.30%|
|1 year (2020-10-15)||-4.07%|
|2 years (2019-10-15)||2.01%|
|3 years (2018-10-12)||N/A|
|5 years (2016-10-12)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-1.29%|
|Return on equity TTM||-52.61%|
|Market capitalisation||$201.6 million|
TTM: trailing 12 months
There are currently 760,441 Celularity shares held short by investors – that's known as Celularity's "short interest". This figure is 22.7% up from 619,740 last month.
There are a few different ways that this level of interest in shorting Celularity shares can be evaluated.
Celularity's "short interest ratio" (SIR) is the quantity of Celularity shares currently shorted divided by the average quantity of Celularity shares traded daily (recently around 108945.70200573). Celularity's SIR currently stands at 6.98. In other words for every 100,000 Celularity shares traded daily on the market, roughly 6980 shares are currently held short.
However Celularity's short interest can also be evaluated against the total number of Celularity shares, or, against the total number of tradable Celularity shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Celularity's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Celularity shares in existence, roughly 40 shares are currently held short) or 0.0307% of the tradable shares (for every 100,000 tradable Celularity shares, roughly 31 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Celularity.
Find out more about how you can short Celularity stock.
We're not expecting Celularity to pay a dividend over the next 12 months.
Celularity Inc. , a biopharmaceutical company, develops placental-derived off-the-shelf therapeutic and cellular medicines for cancer, infectious diseases, and degenerative diseases. The company offers Biovance, a human amniotic membrane allograft that provides a protective cover and supports the body's wound healing processes; and Interfyl, a connective tissue matrix for various surgical applications when there is a need to replace and supplement damaged or inadequate integumental tissue. It also offers allogeneic placenta-derived cell therapy product candidates. The company was incorporated in 2016 and is based in Florham Park, New Jersey. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.